Published in Pharma Investments, Ventures and Law Weekly, September 24th, 2006
Commenting on the results for the fourth quarter, Michael J. Valentino, president and CEO, said, "This quarter was marked not only by solid financial performance, but also by important strategic initiatives that support our long-term diversification strategy. We have been actively engaged in building our product portfolio and preparing for future growth. The acquisition of Delsym in June represents an excellent strategic fit for us and gives us access to another proprietary drug delivery platform technology.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly